Mycoplasma gallisepticum (MG) is an important poultry pathogen that causes respiratory disease and loss of production worldwide, and is currently controlled with live attenuated vaccines. These vaccines have limitations as they vary in their pathogenicity, the protection afforded and their transmissibility, but have been shown to effectively reduce losses associated with challenge in the field. A live attenuated vaccine, ts-11, has been used for the control of M. gallisepticum in several countries. This vaccine is highly dose-dependent and the flock antibody response is weak. GapA is the primary cytadherence molecule in M. gallisepticum, and the absence of GapA expression has been observed in the vast majority of cells in the ts-11 vaccine strain. In this study the immunogenicity of a GapA + M. gallisepticum ts-11 vaccine was investigated in specific-pathogen-free chickens. Birds vaccinated with GapA + M. gallisepticum ts-11 were protected against clinical signs of disease following challenge with virulent M. gallisepticum, and GapA + M. gallisepticum ts-11 was shown to be non-pathogenic and more immunogenic at a lower dose than the currently available M. gallisepticum ts-11 vaccine. Thus, GapA + M. gallisepticum ts-11 appears to have improved potential as a vaccine candidate.
INTRODUCTION
Mycoplasma gallisepticum (MG) is a major pathogen of gallinaceous and some non-gallinaceous avian species, and is the primary cause of chronic respiratory disease in chickens and of infectious sinusitis in turkeys (Kleven et al., 1998; Stipkovits & Kempf, 1996) . It is a highly transmissible organism, and clinical signs of infection include rales, coughing, nasal discharge, sinusitis and air sacculitis, leading to reduced egg production, hatchability, feed conversion efficiency and weight gain, and increased mortality and carcass condemnation (Mohammed et al., 1987) . The prevention of exposure of flocks to wild-type challenge by intense biosecurity and biosurveillance via serological monitoring is considered the first choice in control practices (Stipkovits & Kempf, 1996) . Vaccination with live attenuated vaccines is an option for controlling M. gallisepticum infection when the prevention of exposure is impossible (Whithear, 1996) .
The M. gallisepticum vaccine strain ts-11 is a temperaturesensitive (ts) mutant generated by chemical mutagenesis of a moderately virulent Australian field isolate (strain 80083), and has a ts phenotype, with normal growth at 33 u C but reduced growth at 39.5 u C. A single dose by eye-drop application results in colonization of the upper respiratory tract and induces long-term immunity (Whithear et al., 1990a, b) . However, this vaccine is highly dose-dependent (Noormohammadi et al., 2002a) , and serological monitoring of vaccinated flocks has been difficult because of the low level of antibodies induced by ts-11 in some birds, particularly as detected by the rapid serum agglutination (RSA) test (Noormohammadi et al., 2002b) .
Pathogenic mycoplasmas are typically non-invasive organisms and colonize epithelial surfaces of host tissues. Attachment to target cells is mediated by interactions between mycoplasma cytadhesins and their corresponding host cell receptors (Geary & Gabridge, 1987; Geary et al., 1989) . GapA or MGC1, a 105 kDa protein, is thought to be the primary cytadhesin molecule in M. gallisepticum (Goh et al., 1998; Keeler et al., 1996) . Recent studies on the molecular mechanisms of cytadherence have revealed a complex multifactorial cytadhesion process involving the primary cytadhesin molecule GapA, and possibly also a number of putative cytadherence-related molecules. Prolonged colonization and survival of M. gallisepticum in the host is thought to require both the cytadhesin and cytadherence-related molecules (Papazisi et al., 2000) . The cytadherence-related molecule CrmA, or MGC3, a 116 kDa protein, has significant sequence homology with the Mycoplasma pneumoniae ORF 6 gene product, which has been shown to play a role as an accessory protein in P1-mediated cytadherence (Papazisi et al., 2000; Yoshida et al., 2000) . The crmA gene is located downstream of the gapA gene, as part of the same operon (Papazisi et al., 2000) . Both GapA and CrmA are expressed in virulent M. gallisepticum strain R-low (Rodriguez & Kleven, 1980) , and co-expression of GapA and CrmA is essential for cytadherence and virulence in M. gallisepticum (Papazisi et al., 2002) . The absence of GapA, but not CrmA, has been observed in the ts-11 vaccine strain (Mudahi-Orenstein et al., 2003) . Comparative analysis of the DNA sequences of gapA from ts-11 and its parent 80083 has revealed a 20 bp reiterated sequence, and the lack of expression of GapA in M. gallisepticum ts-11 has been correlated with the frameshift that results from this sequence duplication. The loss of this DNA repeat and re-expression of GapA in ts-11 reisolates from infected chickens suggest that expression of GapA is necessary for continued colonization (Kanci et al., 2004) .
The aim of this work was to study the safety of, and the protective immune response to, GapA + M. gallisepticum ts-11. Protection induced by this vaccine strain was assessed by challenging vaccinated specific-pathogen-free (SPF) chickens with the virulent wild-type M. gallisepticum strain Ap3AS (Soeripto et al., 1989) . Birds vaccinated with GapA + M. gallisepticum ts-11 were compared with birds inoculated with medium alone and birds vaccinated with the commercial M. gallisepticum ts-11 vaccine. Weight gain, anti-M. gallisepticum antibody responses, gross air sac lesions, tracheal histopathology and tracheal B lymphocyte populations were compared.
METHODS
Preparation of vaccine and challenge culture. The GapA + M. gallisepticum ts-11 strain was isolated from an M. gallisepticum ts-11 working seed culture and selected for expression of GapA by plating the culture, picking single colonies and examining them by PCR. The PCR used a pair of PCR primers (Table 1) designed to amplify a 120 bp region in gapA that contains a 20 bp duplication, resulting in premature truncation of GapA (Kanci et al., 2004) . Clones producing a product of 100 bp (without the 20 bp duplication) were further screened by immunoblotting using specific antisera to GapA to detect full-length protein (Kanci et al., 2004) . Culture of the organism was performed in mycoplasma broth (MB) (7.5 g trypticase peptone, 2.5 g phytone peptone, 0.5 g thiotone peptone, 5 g yeast extract, 0.25 g benzyl penicillin, 5 g NaCl, 0.4 g KCl, 0.35 g MgSO 4 . 7H 2 O, 0.05 g Na 2 HPO 4 , 0.1 g KH 2 PO 4 , 1 g glucose, 1.5 ml 1.6 % phenol red solution, 100 ml inactivated swine serum, 10 ml 1 % NAD solution, 10 ml 0.2 % DNA solution, 10 ml yeast autohydrolysate, 1.5 ml 10 % thallium acetate solution, 800 ml distilled water, pH adjusted to 8.1). For vaccination, an ampoule of GapA + M. gallisepticum ts-11 culture (stored at 280 uC) was thawed at 37 uC, diluted 1 : 10 in MB and incubated for 24 h at 33 uC. Alternatively, commercially available M. gallisepticum ts-11 vaccine (Vaxsafe M. gallisepticum ts-11, Bioproperties) was used as recommended by the manufacturer. For challenge, an ampoule of the wildtype M. gallisepticum AP3AS culture (stored at 280 uC) was thawed at 37 uC, diluted 1 : 10 in MB and incubated for 18 h at 37 uC. All experiments were performed under Animal Ethics Committee approval number 06178.
Experimental design. Three groups of four-week-old White Leghorn SPF chickens were housed separately (40 chickens per group) in positive-pressure fibreglass isolators. At day 0, chickens were inoculated by eye-drop with 30 ml MB (group 1), 30 ml Vaxsafe M. gallisepticum ts-11 culture (group 2) or 30 ml GapA + M. gallisepticum ts-11 vaccine (group 3). Twenty-one days after vaccination, 10 birds from each of the groups were euthanized by exposure to 100 % carbon dioxide and necropsied. Fifteen of the remaining birds in each group were challenged by aerosol exposure to Ap3AS and then housed in a single separate isolator. The remaining 15 birds (vaccinated but not challenged) in each group (groups 4, 5 and 6) were kept until day 35 after vaccination. At day 35 (2 weeks after challenge), all birds were euthanized and necropsied.
Collection of samples. Blood samples were collected from all chickens prior to vaccination, challenge and euthanasia. Blood samples were allowed to clot overnight at 4 uC and sera were then collected. The body weight of each bird was measured before immunization and at necropsy.
Air sac lesions were scored grossly for severity on a scale of 0 to 3, as described previously (Nunoya et al., 1987) . A cumulative lesion score was then calculated for each bird by adding the scores of six air sacs.
Swabs were taken from the air sacs and upper trachea of each bird. The swabs were used to inoculate mycoplasma agar (MA) plates, which had the same composition as MB except that glucose and phenol red were omitted and the medium was solidified with 1 % Improved M. gallisepticum ts-11 vaccine bacteriological agar (Oxoid), and then placed in 1 ml MB. MA plates were incubated at 33 uC and examined under a binocular dissecting microscope after 7-10 days. MB cultures were incubated at 33 uC and examined for a change in the colour of the indicator.
Sections of the upper, middle and lower trachea were collected from each bird and fixed in 10 % neutral buffered formalin for histological examination. For immunohistochemistry, segments of trachea were placed in Tissue-Tek O.C.T. embedding compound (Sakura) and immediately frozen in liquid nitrogen. All frozen tissues were stored at -70 uC until use.
Identification of M. gallisepticum. DNA was extracted from those broths showing a colour change and used as template in PCRs. Each PCR was performed using 1.5 U GoTaq DNA polymerase (Promega) in a 25 ml reaction mix containing 1.5 mM MgCl 2 , 200 mM of each dNTP and 1 mM of each primer. The primers used in this study are shown in Table 1 . A region of the 16S rRNA gene of M. gallisepticum was amplified (García et al., 2005) to confirm the presence of M. gallisepticum DNA in the sample. The expected product was 183 bp in size. A fragment of gapA was amplified to differentiate between the vaccine strains administered (Kanci et al., 2004) . The expected product size for Vaxsafe M. gallisepticum ts-11 was 120 bp and for GapA + M. gallisepticum ts-11 it was 100 bp. A portion of the M. gallisepticum ts-11 vlhA gene was amplified using the primer pair WCNewATFor and WBNewAURev to confirm the presence of the vaccine strain and the challenge strain. The expected product size for Vaxsafe M. gallisepticum ts-11 and GapA + M. gallisepticum ts-11 was 229 bp, but no amplification was expected for Ap3AS. The number of colonies that had grown on plates was counted, or estimated if there was a large number of colonies.
Histopathological examination. Tracheal sections were cut and stained with haematoxylin and eosin. The mean mucosal thickness of the trachea of each bird was determined by measuring the thickness at four points transected by vertical and horizontal lines on the upper, middle and lower sections of the trachea, and the histological lesions in upper, middle and lower sections of trachea were scored for severity on a scale of 0 to 3, as described by Nunoya et al. (1987) .
Serology
RSA test. The RSA test for antibodies against M. gallisepticum was performed with stained agglutination antigen (Intervet), and results were scored on a scale of 0 to 4, as described by Whithear (1993) .
M. gallisepticum IgG ELISA. An indirect ELISA was performed using ts-11 VlhA as coating antigen, as described previously (Noormohammadi et al., 2002a) , with some modifications. Briefly, the optimal antigen concentration and test serum dilution were determined. Individual wells of 96-well flat-bottomed plates (Nunc) were coated with 50 ml antigen diluted in carbonate buffer (0.032 M Na 2 CO 3 , 0.068 M NaHCO 3 , pH 9.6) and the plates were incubated overnight at 4 uC. The wells were washed with avian washing buffer (AWB) (29.22 g NaCl and 0.5 ml Tween-20 in 1 l PBS), followed by a wash with reverse osmosis (RO) water, then incubated for 1.5 h at 37 uC with 150 ml blocking buffer (1 % gelatin in carbonate buffer) per well, and washed as above. Test sera were diluted 1 : 100 in AWB with 1 % BSA and added in 50 ml volumes to the wells, and then the plates were incubated for 1 h at 37 uC. The wells were washed with AWB, then 50 ml horseradish peroxidase (HRP)-conjugated rabbit anti-chicken IgG (Chemicon) diluted 1 : 1000 in AWB with 1 % BSA was added to each well, and the plate was incubated for 1 h at 37 uC. The wells were washed as before, and 50 ml 2,29-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) substrate (KPL) was added to each well. The reactions were stopped after 30 min by addition of 50 ml MilliQ water and the absorbance was measured at 414 nm. The standard M. gallisepticum reactive serum was assayed at a 1 : 15 dilution and with serial threefold dilutions to 1 : 32 805.
Analysis of tracheal B lymphocyte populations following vaccination. Tracheal B lymphocyte populations were examined by immunohistochemical staining with a monoclonal antibody against a B cell marker (Bu-1). Frozen 5 mm sections of the upper, middle and lower trachea, collected from each bird 5 weeks after vaccination, were stained as described previously (Gaunson et al., 2000) . The monoclonal antibody specific for Bu-1 (mouse anti-chicken Bu-1, Southern Biotechnology) was used at a dilution of 1 : 100. HRPconjugated sheep anti-mouse IgG (Chemicon) was used at a dilution of 1 : 100. Bound antibody was detected with 3,39-diaminobenzidine (DAB) (Sigma-Aldrich). Cells were counterstained with Mayer's haematoxylin (Sigma-Aldrich). Spleen sections were also stained and used as positive controls. Each tracheal section was examined microscopically, and the numbers of clusters of positively stained cells were recorded (Devlin et al., 2010) . The area of stained cells in each of the B cell clusters was analysed in photomicrographs using Image-Pro Plus (Media Cybernetics).
Stability of the ts phenotype of GapA + M. gallisepticum ts-11
reisolates. Viable counts of reisolates from GapA + M. gallisepticum ts-11-inoculated birds obtained 3 and 5 weeks after vaccination were compared at 33 and 39.5 uC to assess whether passage in the bird had altered the ts phenotype.
Statistical analyses. The mean percentage body weight gains for each group were analysed for differences using a one-way analysis of variance (ANOVA) and Student's t test (Minitab v15 for Windows). Median RSA scores, tracheal lesion scores and air sac lesion scores for each experimental group were compared using Mann-Whitney U tests. The proportions of birds with detectable antibody responses and with air sac lesions were compared using Fisher's exact test. Mean mucosal thicknesses in the upper, middle and lower trachea were compared using Student's t test and a one-way ANOVA. The differences in absorbance values obtained in the M. gallisepticum IgG ELISA for sera from birds in each of the experimental groups were analysed using Student's t test. The mean number of clusters of Bu-1-positive cells per field of view and the mean cross-sectional area of B cells in each cluster in the tracheal mucosa were compared between groups using Student's t test. A P value ¡0.05 was regarded as significant.
RESULTS

Concentration of M. gallisepticum vaccines and challenge
The concentrations of the M. gallisepticum strains used for vaccination and challenge were 9.2610 8 colour changing units (CCU) ml 21 at 33 u C for Vaxsafe M. gallisepticum ts-11, 9.2610 6 CCU ml 21 at 33 u C for GapA + M. gallisepticum ts-11 and 2.2610 5 CCU ml 21 at 37 u C for M. gallisepticum Ap3AS.
RSA scores
Following vaccination and challenge, anti-M. gallisepticum antibody concentrations were assessed semiquantitatively by RSA. No antibodies against M. gallisepticum were detected in the serum of any bird at the time of vaccination. None of the chickens in the negative control groups (1 and 4) had any detectable antibody against M. gallisepticum at the time of necropsy. In group 2, which was vaccinated with Vaxsafe M. gallisepticum ts-11, 30 % of the birds were positive (RSA ¢1) by 3 weeks and 58 % by 5 weeks after vaccination (group 5). In group 3, which was vaccinated with GapA + M. gallisepticum ts-11, 83 % of the birds were positive by 3 weeks and 94 % by 5 weeks after vaccination (group 6). The results are summarized in Table 2 .
Gross lesions
After challenge with Ap3AS, gross air sac lesions were most prevalent in birds that had not been vaccinated (group 1). In this group, 10/12 birds had air sac lesions, with total air sac lesion scores ranging from 0.5 to 4.5. Mild air sac lesions were also observed in 4/13 birds in group 2 (vaccinated with Vaxsafe M. gallisepticum ts-11) and 2/14 birds in group 3 (vaccinated with GapA + M. gallisepticum ts-11). There was no significant difference between the gross air sac lesion scores in the group inoculated with MG medium and the group vaccinated with Vaxsafe M. gallisepticum ts-11, but there was a significant difference between the group inoculated with MG medium and the group vaccinated with GapA + M. gallisepticum ts-11 (P50.03). There were no lesions in any of the unchallenged birds (groups 4, 5 and 6). The results are summarized in Table 3 .
Reisolation of M. gallisepticum M. gallisepticum was frequently isolated from tracheal swabs but not from the air sacs. Broth cultures from each group showing a colour change indicative of mycoplasma growth were confirmed to contain M. gallisepticum by PCR.
On day 21, in the unchallenged groups, M. gallisepticum was reisolated on MA plates from the tracheas of 3/10 birds in group 8 (Vaxsafe M. gallisepticum ts-11-vaccinated) and 4/10 birds in group 9 (GapA + M. gallisepticum ts-11-vaccinated), and in broth from 2/10 birds in group 8 and 6/ 10 birds in group 9.
On day 35, in the unchallenged birds, M. gallisepticum was not recovered on MA plates from swabs of the tracheas of any of 14 birds in group 5 (Vaxsafe M. gallisepticum ts-11-vaccinated), but was recovered from the tracheas of 4/16 birds in group 6 (GapA + M. gallisepticum ts-11-vaccinated), while 2/14 birds in group 5 and 5/16 birds in group 6 yielded positive broth cultures. PCR amplification confirmed that the only mycoplasmas reisolated from groups 5, 6, 8 and 9 were the vaccine strain that had been administered to that group.
After challenge, M. gallisepticum was recovered on MA plates from the air sacs of 1/12 birds in group 1 (inoculated with MG medium) and from the tracheas of 9/12 birds. In group 2 (Vaxsafe M. gallisepticum ts-11-vaccinated), M. gallisepticum was recovered on MA plates from swabs of the tracheas of 7/13 birds and in group 3 (GapA + M. gallisepticum ts-11 vaccinated) from 8/14 birds. In broth cultures of groups 1, 2 and 3, only 1/12, 2/13 and 0/14 of the birds, respectively, had concentrations of M. gallisepticum detectable by PCR on swabs of their tracheas. PCR using strain-specific primers demonstrated that the only mycoplasmas detected were strain Ap3AS. The results are shown in Table 4 .
Weight gains of chickens
There was no significant difference in weight gain between unchallenged birds inoculated with Vaxsafe M. gallisepticum ts-11 and GapA + M. gallisepticum ts-11 at day 21 (groups 2 and 3) or day 35 (groups 5 and 6) after vaccination. However, at day 35 (day 14 after challenge), the unvaccinated chickens (group 1) had a significantly lower mean weight gain than the chickens in group 2 (Vaxsafe M. gallisepticum Improved M. gallisepticum ts-11 vaccine ts-11-vaccinated) (P50.03), but not in comparison with the birds in group 3 (GapA + M. gallisepticum ts-11-vaccinated), and there was no significant difference in the mean weight gains of the birds in groups 2 and 3.
The mean weight gain of the chickens in group 4 (unvaccinated and unchallenged) was significantly lower than that of the birds in group 5 (Vaxsafe M. gallisepticum ts-11-vaccinated, unchallenged) (P50.002) and group 6 (GapA + M. gallisepticum ts-11-vaccinated, unchallenged) (P50.01). The results are shown in Table 5 .
Tracheal mucosal thickness and lesions
The mean tracheal mucosal thicknesses are shown in Table  6 . The mean mucosal thicknesses of the upper, middle and lower tracheas of the birds in group 1 (unvaccinated, challenged) were significantly greater than those of the birds in group 3 (GapA + M. gallisepticum ts-11-vaccinated, challenged) (P,0.01). The mean mucosal thickness of the upper trachea of the birds in group 1 was significantly greater than that of the birds in group 2 (Vaxsafe M. gallisepticum ts-11-vaccinated, challenged) (P50.05). However, there was no significant difference in mucosal thicknesses between these two groups in the middle and lower sections of the trachea. Mean mucosal thicknesses in all three sections of the trachea were significantly lower in the birds in group 3 than in the birds in group 2 (P,0.05). There were no significant differences in the mean mucosal thicknesses of the upper, middle and lower tracheas of the birds in group 3 (GapA + M. gallisepticum ts-11-vaccinated, challenged) and group 4 (unvaccinated, unchallenged), group 5 (Vaxsafe M. gallisepticum ts-11-vaccinated, unchallenged) and group 6 (GapA + M. gallisepticum ts-11-vaccinated, unchallenged). mucosa. The median tracheal lesion scores are shown in Table 7 . The median tracheal lesion scores were significantly higher for the birds in group 1 (unvaccinated, challenged) than for the birds in group 2 (Vaxsafe M. gallisepticum ts-11-vaccinated, challenged) (P,0.005) and group 3 (GapA + M. gallisepticum ts-11-vaccinated, challenged) (P,0.002). No significant differences were seen in the middle and lower tracheal lesion scores for birds in groups 2 and 3. Only the upper tracheal lesion scores for the birds in group 2 were significantly greater than those for the birds in group 3 (P50.001). There were no significant differences in the median tracheal lesion scores for the upper, middle and lower tracheas of the birds in group 3 (GapA + M. gallisepticum ts-11-vaccinated, challenged) and group 4 (unvaccinated, unchallenged), group 5 (Vaxsafe M. gallisepticum ts-11-vaccinated, unchallenged) and group 6 (GapA + M. gallisepticum ts-11-vaccinated, unchallenged).
Tracheal lesions were characterized by the infiltration of inflammatory cells and the formation of follicles in the
Detection of M. gallisepticum specific humoral immunity in chickens
The mean optical density, SD, and the number of positive sera in each group as detected by ts-11 VlhA ELISA are shown in Table 8 . No serum from the unvaccinated chickens (group 1) produced an optical density above the cut-off point (mean+4SD for group 1). There was no significant difference between the optical densities for group 2 (Vaxsafe M. gallisepticum ts-11-vaccinated) and group 3 (GapA + M. gallisepticum ts-11-vaccinated) at day 14 after vaccination. The optical densities were significantly higher for group 3 at day 21 (P50.001) and day 35 (P50.008) after vaccination.
Analysis of tracheal B lymphocyte populations following vaccination
B lymphocyte populations in the tracheal mucosae of vaccinated, unchallenged birds were investigated using immunohistochemical staining. Most of the B lymphocytes formed clusters in the mucosa, although some were also observed scattered throughout the mucosa. The analysis of tracheal B lymphocyte populations is shown in Table 9 . The size and number of B lymphocyte clusters were compared between groups. No B lymphocytes were detected in the tracheal sections from unvaccinated birds (group 1). Tracheal sections from birds vaccinated with Vaxsafe M. gallisepticum ts-11 (group 2) had significantly lower numbers of B lymphocyte clusters than tracheal sections from birds vaccinated with GapA + M. gallisepticum ts-11 (group 3) (P50.001). There was no significant difference between the birds in groups 2 and 3 in the mean area of stained cells per cluster or the mean area of stained cells per section. In group 3, aggregations of B lymphocytes were observed along the upper, middle and lower trachea, whereas in group 2, the B lymphocyte clusters were limited to lower tracheal sections.
Stability of the ts phenotype of GapA + M. gallisepticum ts-11 reisolates
The differential viable counts confirmed that GapA + M. gallisepticum ts-11 reisolated from vaccinated birds 3 and 5 weeks after inoculation retained the ts phenotype.
DISCUSSION
The failure of M. gallisepticum ts-11 to consistently elicit an antibody response poses a problem when assessing the vaccination status of a flock. The dose of vaccine administered can be crucial for successful vaccination with M. gallisepticum ts-11. However, the route of administration, host susceptibility, and factors such as the genotype and physiological status of the birds, may also affect the minimal effective dose of the vaccine (Whithear et al., 1990a) . The recommended eye-drop dose of M. gallisepticum ts-11 is ¢10 7.7 CCU (Whithear, 1996) , and vaccination with M. gallisepticum ts-11 has been recommended only in birds 4 weeks of age and older to ensure that a protective response is elicited against subsequent challenge (Gaunson et al., 2006b) . In this experiment, four-week-old birds were used, and the safety and efficacy of GapA + M. gallisepticum ts-11 as a vaccine were assessed.
Anti-M. gallisepticum antibody, as measured by RSA, was more readily detectable in the group vaccinated with GapA + M. gallisepticum ts-11 (group 3), with a greater number of positive birds, than in the group vaccinated with Vaxsafe M. gallisepticum ts-11 (group 2) at 2, 3 and 5 weeks (groups 5 and 6) after vaccination. The median RSA score was also significantly higher in the group vaccinated with GapA + M. gallisepticum ts-11. The dose of GapA + M. gallisepticum ts-11 (9.2610 6 CCU ml
21
) was 100-fold lower than that of Vaxsafe M. gallisepticum ts-11 (9.2610 8 CCU ml
), but it still elicited a better serum antibody response. GapA + M. gallisepticum ts-11 was able to stimulate production of an antibody response detectable by ELISA in birds 2 weeks after vaccination, with the number of positive birds continuing to increase for a further 3 weeks. It has been established that the ts-11 strain of M. gallisepticum does not colonize the air sacs (Whithear et al., 1990b) , so isolation from the air sacs and production of air sac lesions were not expected in unchallenged birds. There were no visible air sac lesions in birds vaccinated with GapA + M. gallisepticum ts-11 or Vaxsafe M. gallisepticum ts-11 at 3 or 5 weeks after inoculation. This indicates that the GapA + M. gallisepticum ts-11 strain has a low level of pathogenicity similar to that of Vaxsafe M. gallisepticum ts-11. In challenged birds, minor air sac lesions were observed in GapA + M. gallisepticum ts-11-vaccinated birds, but these were less severe than those seen in Vaxsafe M. gallisepticum ts-11-vaccinated birds and much less severe than those seen in unvaccinated birds. These data indicate that GapA + M. gallisepticum ts-11 may provide protection similar to or better than that provided by Vaxsafe M. gallisepticum ts-11.
The ts-11 strain was selected for its ability to multiply in the upper respiratory tract to an extent sufficient to stimulate long-term protective immunity, but not at core body temperature (Whithear et al., 1990b) . In this experiment, Vaxsafe M. gallisepticum ts-11 was reisolated from the tracheas of 4/24 birds (groups 5 and 8) in broth, whereas GapA + M. gallisepticum ts-11 was reisolated from 11/26 birds (groups 6 and 9). Reisolation on agar was only possible for the first 21 days after vaccination of birds with Vaxsafe M. gallisepticum ts-11, but GapA + M. gallisepticum ts-11 was reisolated from 4/16 birds 35 days after vaccination. These results indicate that GapA + M. gallisepticum ts-11 colonized and persisted in the tracheal mucosa better than Vaxsafe M. gallisepticum ts-11.
At day 21 after vaccination, the weight gains of all groups were similar, but at day 35 after vaccination, the weight gain of the vaccinated birds was significantly greater than that of the unvaccinated, control group. After challenge with Ap3AS, the weight gain of the Vaxsafe M. gallisepticum ts-11-vaccinated birds was significantly greater than that of unvaccinated birds, but was not significantly different from that of the birds vaccinated with GapA + M. gallisepticum ts-11. This suggests that with respect to weight gain, vaccination with GapA + M. gallisepticum ts-11 provides protection similar to that provided by Vaxsafe M. gallisepticum ts-11 against the effects of infection with virulent M. gallisepticum.
Histopathological examination of tracheal sections has been used as a measure of protection against challenge with virulent M. gallisepticum. The tracheal mucosal thickness of GapA + M. gallisepticum ts-11-vaccinated birds after challenge was similar in the upper, middle and lower sections of the trachea, and significantly less than that of unvaccinated birds at all three sites after challenge. In contrast, there was no significant difference after challenge between the mucosal thickness of birds vaccinated with Vaxsafe M. gallisepticum ts-11 and unvaccinated birds in the middle and lower sections of the trachea. This suggests that GapA + M. gallisepticum ts-11 can more effectively prevent the damage caused by infection with wild-type M. gallisepticum than Vaxsafe M. gallisepticum ts-11, particularly in the lower trachea.
Extensive inflammatory cell infiltration was observed in the tracheal mucosa of most of the unvaccinated birds after challenge. Moderate upper tracheal lesions were seen in the birds vaccinated with Vaxsafe M. gallisepticum ts-11 following challenge with virulent M. gallisepticum, and these were significantly more severe than the upper tracheal lesions seen in the birds vaccinated with GapA + M. gallisepticum ts-11 after challenge. In the middle and lower trachea there were some lesions in Vaxsafe M. gallisepticum ts-11-vaccinated birds, but the severity of these was not significantly different from those seen in birds vaccinated with GapA + M. gallisepticum ts-11 after challenge. This further suggests the greater protective efficacy of vaccination with GapA + M. gallisepticum ts-11 against infection with wild-type M. gallisepticum.
The ts-11 VlhA ELISA has been shown to be a reliable assay for specific and sensitive detection of serum antibodies against M. gallisepticum (Noormohammadi et al., 2002a) , and chickens vaccinated with Vaxsafe M. gallisepticum ts-11 that have no or low levels of serum antibody detectable by RSA have been shown to still have significant protection against challenge with virulent M. gallisepticum (Noormohammadi et al., 2002b) . In this study, it was found that the ts-11 VlhA ELISA had a sensitivity superior to that of RSA, particularly in birds vaccinated with Vaxsafe M. gallisepticum ts-11. There was only a slight difference in sensitivity between RSA and the ts-11 VlhA ELISA in birds vaccinated with GapA + M. gallisepticum ts-11. Thus, the RSA test could be used effectively as an indicator of the flock response to vaccination with GapA + M. gallisepticum ts-11.
M. gallisepticum causes a lymphoproliferative response in the tracheal mucosa of infected birds (Gaunson et al., , and this response predominantly consists of proliferating B cells (Gaunson et al., 2006a) . Birds vaccinated with GapA + M. gallisepticum ts-11 had a significantly greater number of B lymphocyte clusters in their tracheal mucosa than birds vaccinated with Vaxsafe M. gallisepticum ts-11. This suggests that greater stimulation of B lymphocytes in the tracheal mucosa and differentiation of these into antibody-producing plasma cells may be responsible for the better serum antibody response in GapA + M. gallisepticum ts-11-vaccinated birds and possibly also the better protective immunity seen in these birds.
The viable counts of the reisolates obtained 3 and 5 weeks after inoculation and the absence of air sac lesions at necropsy confirmed that GapA + M. gallisepticum ts-11 retained its ts phenotype and did not regain pathogenicity.
The experimental studies described here demonstrated that eye-drop vaccination with GapA + M. gallisepticum ts-11 not only induced an antibody response detectable by RSA but also did so at a lower dose than Vaxsafe MG ts-11, and with respect to weight gain protected birds from the effects of infection with virulent M. gallisepticum. It also prevented the development of air sac lesions and reduced damage to the trachea. Under well-controlled experimental conditions, the GapA + M. gallisepticum ts-11 vaccine outperformed the commercially available Vaxsafe M. gallisepticum ts-11 vaccine. Based on these initial findings, GapA + M. gallisepticum ts-11 is a promising vaccine candidate for the prevention of avian mycoplasmosis.
